Fulvestrant in advanced breast cancer: evidence to date and place in therapy

Fulvestrant in advanced breast cancer: evidence to date and place in therapy

Breast cancer is a classical hormone-dependent tumour; therefore, endocrine therapy is the mainstay of treatment for hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer. Until recently, classical endocrine agents such as tamoxifen, steroidal and nonsteroidal ar...

Full description

Bibliographic Details
Main Author:	Katalin Boér
Format:	Article
Language:	English
Published:	SAGE Publishing 2017-07-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/1758834017711097

Similar Items

Fulvestrant in endocrine therapy of recurrent and metastatic breast cancer
by: L Yu Vladimirova
Published: (2016-12-01)

ENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANT
by: J.F.R. Robertson, et al.
Published: (2014-09-01)

Fulvestrant in treatment for metastatic breast cancer
by: L. Yu. Vladimirova, et al.
Published: (2019-12-01)

Fulvestrant in hormone-positive advanced breast cancer: Real-world outcome
by: Indhuja Muthiah Vaikundaraja, et al.
Published: (2020-01-01)

A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis
by: Xu L, et al.
Published: (2018-11-01)

Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence
by: Rocca A, et al.
Published: (2018-08-01)

Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
by: Mi Hwa Heo, et al.
Published: (2019-09-01)

Fulvestrant in the fight against ER-positive advanced breast cancer; lone soldier or an important partner?
by: Ashish Singh
Published: (2020-01-01)

Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy
by: Helena Verdaguer, et al.
Published: (2016-05-01)

Fulvestrant in the treatment of luminal metastatic breast cancer: the balance of effectiveness and safety
by: I. A. Koroleva, et al.
Published: (2020-07-01)

Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis
by: Zhang T, et al.
Published: (2018-11-01)

Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients
by: Jingyu Liu, et al.
Published: (2019-01-01)

Nintedanib in NSCLC: evidence to date and place in therapy
by: Giuseppe Bronte, et al.
Published: (2016-05-01)

The Exposure of Breast Cancer Cells to Fulvestrant and Tamoxifen Modulates Cell Migration Differently
by: Dionysia Lymperatou, et al.
Published: (2013-01-01)

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
by: Peter A. Fasching, et al.
Published: (2020-12-01)

Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
by: H. Hawle, et al.
Published: (2010-04-01)

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
by: Ben O’Leary, et al.
Published: (2018-03-01)

Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells
by: Benedikt Warth, et al.
Published: (2019-01-01)

The efficacy and safety of targeted therapy plus fulvestrant in postmenopausal women with hormone-receptor positive advanced breast cancer: A meta-analysis of randomized-control trials.
by: Gao Chanchan, et al.
Published: (2018-01-01)

Approaches to interpret the outcomes of a network meta-analysis on comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy
by: Jayaraj R, et al.
Published: (2019-04-01)

Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series
by: Rusz O, et al.
Published: (2018-09-01)

Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review
by: Junjie Li, et al.
Published: (2019-05-01)

Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients.
by: Steen Knudsen, et al.
Published: (2014-01-01)

High-Dose Toremifene for Fulvestrant-Resistant Metastatic Breast Cancer: A Report of Two Cases
by: Ryutaro Mori, et al.
Published: (2014-06-01)

Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report
by: Sun B, et al.
Published: (2016-07-01)

Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients
by: Lauren Darrigues, et al.
Published: (2021-03-01)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
by: Iorfida M, et al.
Published: (2020-03-01)

Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant
by: Min He, et al.
Published: (2019-10-01)

Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo.
by: Lijiang Zhang, et al.
Published: (2013-01-01)

Efficacy of fulvestrant in hormone refractory metastatic breast cancer (mBC): a Canadian province experience
by: S. Andrahennadi, et al.
Published: (2021-04-01)

Fulvestrant: One step at a time?
by: P Harish, et al.
Published: (2020-01-01)

Cryoablation In The Management Of Breast Cancer: Evidence To Date
by: Pusceddu C, et al.
Published: (2019-10-01)

Evidence to date: talazoparib in the treatment of breast cancer
by: Exman P, et al.
Published: (2019-07-01)

SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer
by: Carla L. Alves, et al.
Published: (2018-06-01)

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
by: Jill M. Spoerke, et al.
Published: (2016-05-01)

Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase–estrogen receptor axis
by: Xing Huang
Published: (2019-11-01)

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
by: Lillian M. Smyth, et al.
Published: (2021-04-01)

Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience
by: Samitha Andrahennadi, et al.
Published: (2021-08-01)

Galeterone for the treatment of advanced prostate cancer: the evidence to date
by: Bastos DA, et al.
Published: (2016-07-01)

Fulvestrant vne klinicheskikhissledovaniy (opyt otdeleniya khimioterapii)
by: E K Voznyy,, et al.
Published: (2010-12-01)